#United States #San Francisco #Nektar Therapeutics #Rezpegaldesleukin #EADV Congress

Nektar Presents Innovative Findings at EADV 2025

Nektar Therapeutics, a leading clinical-stage biotechnology firm based in San Francisco, has announced exciting outcomes from its ongoing REZOLVE-AD Phase 2b study of Rezpegaldesleukin. This groundbreaking research will be presented as a Late-Breaker Oral Presentation at the prestigious European Academy of Dermatology and Venereology (EADV) Congress, slated for September 17-20, 2025, in Paris.

Overview of the Presentation

During this congress, Nektar will communicate key insights from the 16-week induction phase of the trial, highlighting both primary and secondary endpoints. The presentation recognizes the importance of patient feedback, incorporating multiple outcome assessments gathered from participants throughout the study. Notably, the session will introduce new data from patients who had previously been assigned a placebo and have since transitioned to a high-dose treatment regimen of Rezpegaldesleukin.

Presentation Details

The oral presentation will be led by Dr. Jonathan Silverberg, and is scheduled for September 18, 2025, from 14:45 to 15:00 (local time). Attendees can expect a comprehensive overview of Rezpegaldesleukin's efficacy and safety in treating atopic dermatitis, as detailed in Abstract ID LBA-108.

Location: Paris Nord Conference Center
Session Title: D2T01.3C

Following its live presentation, additional resources and details will be available on Nektar's official website.

In-depth Look at the REZOLVE-AD Study

The REZOLVE-AD clinical trial commenced in October 2023, engaging patients from around 110 sites globally. Remarkably, a significant portion of participants—68%—were treated across various European nations, including Germany, Spain, Poland, and the Czech Republic. In contrast, 16% were based in the United States, 11% in Canada, and 5% in Australia.

To ensure rigorous standards, the trial used a randomization strategy that considered participants' baseline disease severity, defined through the validated vIGA-AD measure (Visual Immune Global Assessment for Atopic Dermatitis). Enrollment criteria necessitated a minimum EASI (Eczema Area and Severity Index) score of 16.0 alongside specific body surface area and disease severity thresholds.

Understanding Rezpegaldesleukin

Rezpegaldesleukin is an innovative, potential first-in-class therapy that aims to restore balance to the immune system in patients experiencing autoimmune and inflammatory illnesses. It works by targeting the interleukin-2 receptor complex, promoting the growth of regulatory T cells that help mitigate the harmful effects of autoimmune responses.

In a recent milestone, the FDA granted Fast Track designation to Rezpegaldesleukin for both moderate-to-severe atopic dermatitis in patients aged 12 and older, and for severe alopecia areata in eligible pediatric and adult patients. This highlights the treatment's potential role in advancing patient care.

The Burden of Atopic Dermatitis

Atopic dermatitis is the most prevalent form of eczema, affecting an estimated 30 million individuals in the U.S. alone. It is characterized by a compromised skin barrier, leading to heightened vulnerability to allergens and irritants, which triggers triggering inflammatory responses. The impact of this condition can severely affect the quality of life for patients, underscoring the urgent need for effective therapeutics.

Final Notes

Nektar Therapeutics has established itself as a pioneer in addressing immunological dysfunction through innovative drug development. With Rezpegaldesleukin as a primary candidate in clinical trials, the company is positioned favorably within the dynamic landscape of treatments for autoimmune disorders.

As Nektar prepares for the EADV 2025 Congress, it promises engaging discussions around cutting-edge approaches to treating autoimmune diseases, especially in the realm of dermatological health. For more updates, visit Nektar's website and follow their progress on LinkedIn.

Conclusion

This presentation at EADV 2025 could prove pivotal, showcasing both the promising therapeutic potential of Rezpegaldesleukin and the commitment of Nektar Therapeutics to transform patient outcomes in the field of dermatology.